Staerz U D, Bevan M J
Basel Institute for Immunology, Switzerland.
Int Rev Immunol. 1989 May;4(2):159-73. doi: 10.3109/08830188909044779.
A technology is described which combines the power of T lymphocytes in eliminating unwanted cells and causing beneficial inflammatory reactions with the great advantages of monoclonal antibodies. We show that heteroconjugate antibodies and hybrid antibodies, in which one of the component binding sites is anti-T-cell receptor and the other component binding is directed against any chosen target antigen, can focus T cells to act at the targeted site. We present experimental evidence for the in vitro efficacy of this system in viral infections and in the elimination of tumor cells. In an in vivo tumor model pilot experiments have been undertaken that resulted in a significant higher rate of survival of animals treated with hybrid antibodies compared to untreated animals.
本文描述了一种技术，该技术将T淋巴细胞在消除不需要的细胞和引发有益炎症反应方面的能力与单克隆抗体的巨大优势相结合。我们发现，异源结合抗体和杂交抗体（其中一个组分结合位点是抗T细胞受体，另一个组分结合针对任何选定的靶抗原）可以使T细胞聚焦于靶位点发挥作用。我们提供了该系统在病毒感染和消除肿瘤细胞方面体外有效性的实验证据。在体内肿瘤模型中已经进行了试点实验，结果显示与未治疗的动物相比，用杂交抗体治疗的动物存活率显著提高。
